Free tool
FAERS Monitor: Upneeq
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 212520 or its brand name (Upneeq, Oxymetazoline Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
2,364
Serious
105
4% of reports
Hospitalization
11
Death reported
2
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective618
- vision blurred311
- eye irritation276
- ocular hyperaemia257
- off label use199
- headache197
- dry eye186
- eye pain183
- mydriasis130
- eye pruritus119
- lacrimation increased90
- swelling of eyelid88
- eye swelling70
- dizziness59
- blood pressure increased50
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2020 | 34 |
| 2021 | 370 |
| 2022 | 439 |
| 2023 | 292 |
| 2024 | 318 |
| 2025 | 274 |
| 2026 | 637 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,795 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| swelling of eyelidSignal | 88 | 126.5 | 102.9 | 10,679 |
| mydriasisSignal | 130 | 91.1 | 77.0 | 11,379 |
| ocular hyperaemiaSignal | 257 | 48.4 | 43.1 | 11,855 |
| eye irritationSignal | 276 | 42.9 | 38.4 | 11,220 |
| dry eyeSignal | 186 | 33.3 | 29.0 | 5,782 |
| eye pruritusSignal | 119 | 31.6 | 26.5 | 3,491 |
| eye painSignal | 183 | 28.9 | 25.2 | 4,907 |
| lacrimation increasedSignal | 90 | 26.6 | 21.7 | 2,186 |
| vision blurredSignal | 311 | 20.2 | 18.2 | 5,679 |
| eye swellingSignal | 70 | 16.8 | 13.3 | 1,022 |
| drug ineffectiveSignal | 618 | 4.2 | 3.9 | 1,587 |
| blood pressure increasedSignal | 50 | 2.9 | 2.2 | 61 |
| headacheSignal | 197 | 2.8 | 2.4 | 232 |
| off label useSignal | 199 | 2.0 | 1.8 | 106 |
| dizziness | 59 | 1.1 | 0.8 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.